Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4YMIS)

• Drug Name: Aldesleukin Drug Info
• Synonyms: Proleukin (TN)

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Approved	[1]
Childhood myelodysplastic syndrome		Approved	[2]
Cutaneous melanoma	2C30	Approved	[3]
Desmoplastic small round cell tumor		Approved	[2]
Leukemia		Approved	[1]
Lung cancer	2C25.0	Approved	[4]
Renal cell carcinoma	2C90	Approved	[5]
Non-hodgkin lymphoma	2B33.5	Phase 2	[5]
Colon cancer	2B90.Z	Investigative	[6]
Gastric cancer	2B72	Investigative	[2]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID: TTD Drug ID: DM4YMIS

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daclizumab	DM6OZQV	Aplastic anemia	3A70	Approved	[8]
AIR-insulin	DM8SYTE	Diabetic complication	5A2Y	Phase 3	[9]
TG-4010	DMWE3GB	Bipolar disorder	6A60	Phase 2/3	[10]
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[11]
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[12]
Carboxyamidotriazole orotate	DMN5JCX	Glioblastoma multiforme	2A00.0	Phase 2	[13]
Leuvectin	DM5LQEI	Melanoma	2C30	Phase 2	[14]
Human interleukin-2	DM0NJWG	Renal cell carcinoma	2C90	Phase 2	[15]
L19-IL-2 fusion protein	DMI2XP1	Lymphoma	2A80-2A86	Phase 2	[16]
Thymoctonan	DM4BLJM	Immune System disease	4A01-4B41	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Modulator	[7]

References

• [1] Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 1993 Sep;46(3):446-514.
• [2] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [3] Aldesleukin. 2018 May 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012C.
• [4] Targeting interleukin-1 and inflammation in lung cancer. Biomark Res. 2022 Jan 27;10(1):5.
• [5] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [6] Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 2008 Jul 1;14(13):4192-9.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [9] The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
• [10] A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
• [11] Clinical pipeline report, company report or official report of Bioniz Therapeutics.
• [12] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [13] J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
• [14] Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
• [15] Clinical pipeline report, company report or official report of Immunservice.
• [16] National Cancer Institute Drug Dictionary (drug id 665656).
• [17] Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7.